1. Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma

3. Introduction

4. Measurement of Asthma Control According to 2006 GINA Guidelines: MAGIC Study

5. Asthma Control in Clinical Practice

6. Severe Asthma Is an Airway Disease

7. Mechanisms of Eosinophilic Asthma

8. GINA-Based Treatment Steps

9. Charcot-Robin-Leyden Crystals (Lysophospholipase From Eosinophils)

10. Charcot-Robin-Leyden Crystals (Lysophospholipase)

11. Curschmann's Spirals

12. What Does This Have to Do With Eosinophils?

13. Sputum Eosinophils

14. Peripheral Blood and Sputum Eosinophils as Biomarkers

15. Longitudinal Relationship Between Activated T Cells, Eosinophils, Cytokines, and Pulmonary Function

16. Clinical Profile of Patients With Asthma in the UK

17. GINA-Based Treatment Steps

18. Add-On Treatment to Discuss in Step 5

19. Anticytokines Against IL-5

20. Mepolizumab for Severe Eosinophilic Asthma (MENSA)

21. Reslizumab for Inadequately Controlled Asthma

22. Reslizumab for Inadequately Controlled Asthma (cont)

23. Change From Baseline in the Oral Glucocorticoid Dose and Asthma Exacerbations: ZONDA Trial

24. Anticytokines Against IL-5

25. Mechanisms of Eosinophilic Asthma

26. Severe Asthma Exacerbations on Dupilumab

27. Effect of SC Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

28. Mechanisms of Eosinophilic Asthma

29. Clinical Trials: Omalizumab Reduced Asthma Exacerbation Rates

30. Clinical Trials: Persistence of Response to Omalizumab Can Be Predicted at 16 Weeks

31. EXALT: Eosinophilic Asthma Predicts Efficacy of Anti-IgE (Omalizumab) in Severe Allergic Asthma

32. Exacerbation Rate Reduction With Mepolizumab Baseline Blood Eosinophil Count

33. Anti-IL-5 Therapy in Eosinophilic Asthma

34. What Is the Relationship Between Blood Eosinophils and Severe Asthma Exacerbations?

35. Step 5: Management in Guidelines

36. Add-On Treatment to Discuss in Step 5

37. When to Use Biologics in Asthma

38. The Nasal Polyp Endotype

39. Effect of Mepolizumab on Total Polyps Score

40. Several (Interdependent) Determinants of Anti-IL-5 Clinical Response in Asthma

41. Blood Eosinophil Count Is a Useful Biomarker to Identify Patients With Severe Eosinophilic Asthma

42. Mepolizumab vs Placebo in the DREAM Trial

43. Conclusion

44. Abbreviations

45. Abbreviations (cont)

46. Abbreviations (cont)

47. Abbreviations (cont)